Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

Modeling Ponatinib Resistance in BCR-ABL1 + Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

Liu Lu, BscHons, Verity Saunders, BScHons, Chung H Kok, PhD, Tamara Leclercq, PhD, Timothy P Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)

Blood (2014) 124 (21): 4515.

https://doi.org/10.1182/blood.V124.21.4515.4515

Published: 2014

Journal Articles

The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels

Deborah White, PhD. FFSc (RCPA), Verity Saunders, BScHons, Laura Eadie, PhD, Yeung David, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 256.

https://doi.org/10.1182/blood.V122.21.256.256

Published: 2013

Journal Articles

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

Devendra K Hiwase, MD, MBBS, FRACP, FRCPA, Laura Eadie, Verity Saunders, Timothy Hughes, MD, MBBS, Deborah L. White, PhD

Blood (2010) 116 (21): 3991.

https://doi.org/10.1182/blood.V116.21.3991.3991

Published: 2010

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Devendra K Hiwase, Jane Engler, Verity Saunders, Deborah L. White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 1205.

https://doi.org/10.1182/blood.V116.21.1205.1205

Published: 2010

Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2288.

https://doi.org/10.1182/blood.V116.21.2288.2288

Published: 2010

Journal Articles

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Jane R. Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, Timothy P. Hughes

Blood (2010) 116 (15): 2776–2778.

https://doi.org/10.1182/blood-2010-01-267013

Published: 2010

Journal Articles

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

Deborah White, Verity Saunders, Phuong Dang, Amity Venables, Steph Zrim, John Reynolds, Steven Quinn, Andrew Zannettino, Timothy Hughes

Blood (2006) 108 (11): 738.

https://doi.org/10.1182/blood.V108.11.738.738

Published: 2006

Journal Articles

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

Deborah White, Phuong Dang, Amity Venables, Verity Saunders, Stephanie Zrim, Andrew Zannettino, Peter Diamond, Steven Quinn, Luen Bik To, Timothy Hughes

Blood (2006) 108 (11): 2144.

https://doi.org/10.1182/blood.V108.11.2144.2144

Published: 2006

Journal Articles

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

Deborah White, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, Timothy Hughes

Blood (2005) 106 (7): 2520–2526.

https://doi.org/10.1182/blood-2005-03-1103

Published: 2005

NARROW

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Modeling Ponatinib Resistance in BCR-ABL1 + Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Imatinib PK: Observations From the TIDEL II Study

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only